<DOC>
	<DOCNO>NCT02349243</DOCNO>
	<brief_summary>This randomize , control , double blind clinical trial . The purpose study investigate weight loss efficacy entacapone . In study , participant randomly divide entacapone placebo group . The percentage change body weight , body mass index , waist circumstance , extent fatty liver , quantity visceral fat , serum insulin , serum triglyceride adverse effect compare two group .</brief_summary>
	<brief_title>Effect Entacapone Bodyweight Loss Obese Population</brief_title>
	<detailed_description>All volunteer clearly understand objective risk present study . Then , volunteer carefully read sign inform consent receive copy sign informed consent . If volunteer agree participate present study sign inform consent , volunteer include . The included participant follow case report form compete appoint researcher . Recruiting stage : To check whether volunteer eligible participate : 1 . All volunteer check accord inclusive exclusive criterion ; 2 . The clinical nutritionist provide diet exercise regime volunteer . Grouping stage : A group 12 Participants enter study time , 1 . To assess performance volunteer comply diet exercise regime ; 2 . Volunteers able comply regime sign inform consent include ; 3 . Every participate receive random number pack opaque envelop ; 4 . Physical examination : blood pressure , heart rate , height , bodyweight , waist hip circumference ; 5 . Laboratory examination : level adiponectin , leptin , resistin , C-reactive protin , insulin , fast blood glucose , haemoglobin A1c , tri glyceride , total cholesterol , LDL cholesterol , HDL cholesterol ; 6 . Extra blood sample ( 20ml ) collect measure level adiponectin , resistin leptin ; 7 . The opaque envelop contain random number open CRA group determine ; 8 . Participants take entacapone placebo physicians researcher instruct make record standard form ; 9 . Participants carry diet exercise regime , measure bodyweight everyday take record . Intervening stage : 1 . Two week first intervention , monthly telephone interview start : 1.1 Ask participant detail take medicine , follow diet exercise regime , present body weight ; 1.2 Ask participant whether discomfort decide whether medical intervention need . 2 . Four week first intervention , monthly hospital interview start : 2.1 The day participant go hospital second interview . 2.1.1 Any drink , food strenuous activity avoid least 8 hour second interview ; 2.1.2 The standard form daily activity bring . 2.2 During interview : 2.2.1 Physical examination：blood pressure , heart rate , height , bodyweight , waist hip circumference ; 2.2.2 The detail participant take medicine , follow diet exercise regime ask ; 2.2.3 Laboratory examination : level adiponectin , leptin , resistin , C-reactive protin , insulin , fast blood glucose , haemoglobin A1c , triglyceride , total cholesterol , LDL cholesterol , HDL cholesterol ; 2.2.4 20ml blood sample collect measure level adiponectin , resistin , leptin expression obese relate gene ; 2.2.5 Abdominal MRI make ; 2.2.6 Any discomfort participant record medical treatment provide necessary ; 2.2.7 The previous standard form daily activity hand CRA blank form provide ; 2.2.8 The untaken drug retrieve , pack record maed ; 2.2.9 Drugs next month distribute relevant record make . 2.3 Participate go back home . 2.3.1 Participants continue take entacapone placebo physicians researcher instruct make record standard form ; 2.3.2 Participants continue carry diet exercise regime , measure bodyweight everyday take record . All data record standard case report form accuracy , completeness timeliness regularly check appoint clinical research associate . The sample size calculate software PASS 11.0 . The alternative hypothesis set Mean 1 &lt; Mean 2 , mean participant entacapone group loss weight participant placebo group . Because pilot study , error set ( 1-β ) =0.8 α=0.1 . According result study tesofensine , another weight loss drug , participant entacapone placebo group estimate loss 2 kg 10 kg respectively . The estimated sample size 30 , 15 arm . The statistical analysis conduct computer software SPSS 17.0.0 ( SPSS Inc , Chicago , Ill ) . All analysis perform accord intention-to-treat principle . The occurrence primary secondary end point compare entacapone placebo group . The categorical data report number proportion , quantitative data report median interquartile range ( IQRs ) mean standard deviation . The categorical data compare use Chi-squared Fisher exact test appropriate . For continuous data , Mann-Whitney U-test use group comparison appropriate . A two-sided p value &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>1 ) Obese define BMI ≥ 28kg/m2 ; 2 ) 18≤ age ≤60 year ; 3 ) Permanent resident Xi'an City , Shaanxi Province , China 1 ) Unable closely follow diet exercise regime ; 2 ) Bodyweight change beyond 4kg within 3 month participate study ; 3 ) Have history myocardial infarction unstable angina within 6 month participate study ; 4 ) With endocrine , neurological , psychiatric malignant disease ; 5 ) History thyroid disease ; 6 ) Cardiac , hepatic renal dysfunction ; 7 ) Have long history use amcinonide ; 8 ) With intestinal malabsorption ; 9 ) With history acute chronic pancreatitis 10 ) With history gastrointestinal surgery ; 11 ) With history bariatric surgery ; 12 ) Using pharmacological drug weight loss ; 13 ) Addicted drug include alcohol ; 14 ) Diabetes ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>obese</keyword>
	<keyword>weight loss</keyword>
	<keyword>entacapone</keyword>
</DOC>